VBL Therapeutics Announces Year End 2017 Financial Results

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced financial results for the quarter and year-ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“VBL has more than $50 million in cash, which will enable us to continue the development of VB-111 and our promising pipeline through 2020,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “We intend to continue the ongoing OVAL trial, our Phase 3 potential registration trial in platinum-resistant ovarian cancer, in collaboration with the GOG Foundation.  We intend to add an interim analysis for evidence of efficacy signal in our OVAL trial, sooner than in our original plan. We expect that the interim readout may be available during the first half of 2019.”

Click here to read the full press release.